Today's Research Report Coverage on Biotech Stocks -- Jaguar Animal Health, Biostage, Cymabay Therapeutics, and Catalyst Biosciences

Thursday, June 15, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 15, 2017 /PRNewswire/ -- has issued research reports on these four stocks: Jaguar

Animal Health Inc. (NASDAQ: JAGX), Biostage Inc. (NASDAQ: BSTG), Cymabay Therapeutics Inc. (NASDAQ: CBAY), and Catalyst Biosciences Inc. (NASDAQ: CBIO). According to Benzinga's research, the iShares NASDAQ Biotechnology Index has been up 10.55% thus
far this year, the NYSE ARCA BIOTECH INDEX has added 18.81%, and the SPDR S&P Biotech has advanced 20.43%. Learn more about these stocks by signing up for their free reports on at:

Jaguar Animal Health 

On Wednesday, shares in San Francisco, California headquartered Jaguar Animal Health Inc. recorded a trading volume of 154,639 shares. The stock ended the session 0.61% higher at $0.62. The Company's shares are trading 19.58% below their 50-day moving average. Moreover, shares of Jaguar Animal Health, which focuses on developing and commercializing gas trointestinal products for companion and production animals, foals, and high value horses, have a Relative Strength Index (RSI) of 31.80.

On June 07th, 2017, Jaguar Animal Health and Napo Pharmaceuticals, Inc., a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, announced the former's launch of, a commercial website for Neonorm™ Foal and Neonorm™ Calf, the Company's lead non-prescription products. Neonorm™ Foal is a natural, clinically tested, non-drug product designed for use as an anti-diarrheal in newborn horses. The free research report on JAGX is available at:


Holliston, Massachusetts headquartered Biostage Inc.'s stock closed the day 0.09% lower at $0.32 with a total trading volume of 275,955 shares. The Company's shares have advanced 2.79% in the past month. The stock is trading 5.17% above its 50-day moving average. Additionally, shares of Biostage, which engages in developing bioengineered organ implants based on its Cellframe technology, have an RSI of 59.38.

On May 22nd, 2017, Biostage announced that, as anticipated, on May 18th, 2017, the Company received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC indicating that its failure to regain compliance with the minimum $1.00 bid price requirement by May 17th, 2017, and its non-compliance with the $2.5-million stockholders' equity requirement as of the quarter ended March 31st, 2017, could serve as a basis for delisting the Company's common stock from The Nasdaq Capital Market, unless it timely requests a hearing before the Nasdaq Hearings Panel. The complimentary report on BSTG can be downloaded at:

Cymabay Therapeutics 

Shares in Newark, California headquartered Cymabay Therapeutics Inc. recorded a trading volume of 591,591 shares, which was above their three months average volume of 318,370 shares. The stock ended yesterday's trading session 2.00% higher at $4.58. The Company's shares have advanced 15.95% in the past month, 7.76% in the previous three months, and 164.74% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 14.24% and 68.42%, respectively. Furthermore, shares of Cymabay Therapeutics, which focuses on developing and commercializing therapies to treat specialty and orphan diseases, have an RSI of 55.68. Visit us today and download our complete research report on CBAY for free at:

Catalyst Biosciences 

South San Francisco, California headquartered Catalyst Biosciences Inc.'s stock finished Wednesday's session 0.93% higher at $4.36 with a total trading volume of 155,011 shares. The Company's shares have advanced 12.66% in the last one month. The stock is trading below its 50-day moving average by 10.46%. Additionally, shares of Catalyst Biosciences, which focuses on developing medicines to address hematology indications, have an RSI of 48.96.

On May 31st, 2017, Catalyst Biosciences announced that the European Medicines Agency Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan medicinal product designation for CB 2679d/ISU304 for the treatment of hemophilia B. CB 2679d, a highly potent, next-generation coagulation Factor IX variant, has demonstrated, in preclinical studies, the potential to normalize human Factor IX levels with a daily subcutaneous injection.

On June 12th, 2017, research firm Chardan Capital Markets initiated a 'Buy' rating on the Company's stock, with a target price of $10 per share. Get free access to your technical report on CBIO at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store